Transition to Subcutaneous Infliximab vs Vedolizumab in Inflammatory Bowel Disease: A Prospective Multicenter Study

Principi, Mariabeatrice; Brescia, Irene Vita; Stasi, Elisa; Mazzuoli, Silvia; D’Uggento, Angela Maria; Equatore, Elena; Lacavalla, Ilaria; Di Leo, Alfredo

doi:10.1007/s10620-024-08631-2

Dig Dis Sci

2024

DOI: 10.1007/s10620-024-08631-2

|View full text |Cite

Transition to Subcutaneous Infliximab vs Vedolizumab in Inflammatory Bowel Disease: A Prospective Multicenter Study

Mariabeatrice Principi,

Irene Vita Brescia,

Elisa Stasi

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Needle or Drip?—Real-World Comparison of Intravenous to Subcutaneous Infliximab and Vedolizumab in the Management of Inflammatory Bowel Diseases

Outtier,

Ferrante

2024

Dig Dis Sci

View full text Add to dashboard Cite

Digestive Diseases and Sciences should prioritize long-term data collection, the economic implications, potential predictors, and assess serum concentrations, all of which will help clarify the overall benefits of this treatment approach.Author's contribution All authors contributed equally to conceptualization and drafting of the submitted manuscript. Data availabilityNo datasets were generated or analyzed during the current study.

show abstract

Needle or Drip?—Real-World Comparison of Intravenous to Subcutaneous Infliximab and Vedolizumab in the Management of Inflammatory Bowel Diseases

Outtier,

Ferrante

2024

Dig Dis Sci

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Transition to Subcutaneous Infliximab vs Vedolizumab in Inflammatory Bowel Disease: A Prospective Multicenter Study

Cited by 1 publication

References 22 publications

Needle or Drip?—Real-World Comparison of Intravenous to Subcutaneous Infliximab and Vedolizumab in the Management of Inflammatory Bowel Diseases

Needle or Drip?—Real-World Comparison of Intravenous to Subcutaneous Infliximab and Vedolizumab in the Management of Inflammatory Bowel Diseases

Contact Info

Product

Resources

About